Horizon Pharma (HZNP) Tops Q1 EPS by 4c

Horizon Pharma (NASDAQ: HZNP) reported Q1 EPS of $0.34, $0.04 better than the analyst estimate of $0.30. Revenue for the quarter came in at $204.7 million versus the consensus estimate of $197.73 million.

The Company confirms its full-year and second-quarter net sales and adjusted EBITDA guidance.

----------------------------------------------------------------------------

                     FY 2016E Guidance     Q2 2016E(1)        2H 2016E(1)

                    ------------------ ------------------ ------------------

                                          22% to 23% of      57% to 59% of

2016 Net sales       $1.025 to $1.050     full-year net      full-year net

                          Billion             sales              sales

----------------------------------------------------------------------------

                                          21% to 22% of      64% to 66% of

2016 Adjusted          $505 to $520    full-year adjusted full-year adjusted

 EBITDA                   Million            EBITDA             EBITDA

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• World Kinect Corporation (WKC) Misses Q1 EPS by 2c, Misses on Revenue
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance